Other headlines:Volcano executive opens NasdaqMerge updates ortho package
An 8-K filing by Amicas with the Securities and Exchange Commission added details to the company's pending acquisition of Emageon. Restrictions built into the deal require the formal tender for Emageon shares to begin no later than March 5 and to remain open at least 20 business days. The goal is to pick up 90% of outstanding shares. If the amount tendered is fewer than that percentage, yet still a majority, however, a "Top-Up Option" allows the purchase of newly issued shares equal to the number needed to achieve the 90% threshold. If the deal is not consummated for reasons tied to Emageon, the to-be-acquired company will be on the hook for a $1.6 million termination fee.
Volcano CEO Scott Huennekens rang the ceremonial opening bell for the Nasdaq this morning at the exchange's broadcast studio at 4 Times Square. Reflecting concerns about deepening recession, stocks were off in early trading.
A new software package from Merge Health combines software tools needed for orthopedic surgical planning, providing the basis for data integration into PACS and electronic medical records. This newest release of Cedara ProPlanner, version 3.1, features semiautomatic calibration, user-defined measurements, and image stitching that help decrease the time and cost of planning for surgeons and vendors. The company's OEM partners can rebrand the package and integrate it into existing PACS solutions, add it to a digital radiography or computed radiography modality, or offer it as a stand-alone workstation.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.